Online Course

State-of-the-Art Clinical Symposium 2020 On-Demand

Date:

Expires Dec 31, 2020

Program Information

CME: 9.75    MOC: 9.75

At this all-virtual clinical symposium, key opinion leaders deliver a range of high-impact content in areas such as therapeutic developments, recent research findings, and scientific advances. On-demand access includes recordings of each lecture and the 10-minute virtual Q&A which followed most lectures. Content and on-demand credit claiming is avaliable through December 31, 2020.

Target Audience
Rheumatologists, physicians, healthcare providers who care for patients with rheumatic diseases, and those interested or engaged in rheumatology research.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Discuss the most up-to-date evidence-based treatment approaches in the management of rheumatic diseases
  • Identify and describe recent scientific and clinical advances regarding the pathogenesis of rheumatic diseases

Program Schedule

Registration Fees

Registration is available until December 31, 2020.

ACR/ARP Member - $176
ACR/ARP nonmember - $260*
ACR/ARP Member (Master, Emeritus) - $91
ACR/ARP Member (Student, Resident, Pre/Post Doctoral Fellow) - $77
ACR Fellow in Training /Program Director - $0**

*Non-member resident/students should contact education@rheumatology.org and include a letter from their program director, chief of service, or faculty advisor to be eligible for reduced fees.

**Program Directors should contact education@rheumatology.org to receive complimentary access.

CME and MOC Information

Accreditation Statement
The American College of Rheumatology is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation Statement
The ACR designates this online activity for a maximum of 9.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activities.

MOC Statement
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 9.75 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Faculty and Disclosures

ACR Disclosure Statement
The ACR is an independent, professional organization that does not endorse specific procedures or products of any pharmaceutical/biotech concern. Educational activities provided by the ACR must demonstrate balance, independence, and scientific rigor. All those in a position to control the content of an activity must disclose all relevant financial relationship(s) with commercial interest(s). For this educational activity, all conflicts of interest have been resolved through peer review and revisions to ensure independence, evidence base, fair balance, and absence of commercial bias.

Faculty participating in an ACR-sponsored activity must disclose to the editorial team and audience any financial or other relationship(s) including, but not limited to:

  1. Stock, stock options or bond holdings in a for-profit corporation or self-directed pension plan
  2. Research grants
  3. Employment (full or part-time)
  4. Ownership or partnership
  5. Consulting fees or other remuneration (payment)
  6. Non-remunerative positions of influence such as officer, board member, trustee, or public spokesperson
  7. Receipt of royalties
  8. Speakers' bureau
  9. Other

The faculty reported the following disclosures.

2020 State-of-the-Art Clinical Symposium Planning Committee

  • Meenakshi Jolly, MD, MS – Rush University7, Pfizer2
  • Narender Annapureddy, MD, MS – No relevant financial relationships to disclose
  • Francesco Boin, MD – No relevant financial relationships to disclose
  • Liana Fraenkel, MD, MPH – No relevant financial relationships to disclose
  • Lianne Gensler, MD – Novartis2, Pfizer2, UCB2, Abbvie5, Galapagos5, Janssen5
  • Manjari Malkani, MD – No relevant financial relationships to disclose
  • Rebecca Manno, MD – Sanofi5, Novartis2, Paradigm Education5
  • Michael Putman, MD – No relevant financial relationships to disclose

2020 State-of-the-Art Clinical Symposium Faculty

  • Francesco Boin, MD – No relevant financial relationships to disclose
  • Eliza F. Chakravarty, MD – No relevant financial relationships to disclose
  • Megan Clowse, MD, MPH – GlaxoSmithKline2
  • Erika Darrah, PhD – No relevant financial relationships to disclose
  • Kevin Deane, MD, PhD – BMS5; Inova Diagnostics Inc.5, 2; Janssen2; Microdrop, Inc5; ThermoFisher Scientific5
  • Mary-Ann Fitzcharles, MD – No relevant financial relationships to disclose
  • Tracy Frech, MD – No relevant financial relationships to disclose
  • Jon Giles, MD, MPH – AbbVie5; Bristol Myers Squibb Co., Ltd.5; Eli Lilly and Co.5; Pfizer2; Roche/Genentech5; UCB Pharma5
  • Laura Hummers, MD – Boehringer Ingelheim5, 2; Corbus Pharmaceuticals2; CSL Behring5, 2; Cumberland2; EICOS2; Glaxo Smith Kline2; Kadmon2
  • Tanaz Kermani, MD – Genentech5, 9, Round table discussion on GCA.
  • Mehrdad Matloubian, MD, PhD – No relevant financial relationships to disclose
  • Joan Merrill, MD – Abbvie5, 8; Amgen5; Astellas5; Astra Zeneca5; Bristol Myers Squibb Co., Ltd.5, 2; Celgene5; Daiichi Sankyo5; EMD Serono5; Glaxo Smith Kline5, 2; ILTOO5; Immupharma5; Incyte5; Janssen5; Lilly5; Remegen5; Servier5; Zencor2
  • John Reveille, MD – Eli Lilly5,2,9; Novartis5, UCB5, Janssen2, Pfizer9
  • James T. Rosenbaum, MD – AbbVie5
  • Ami Shah, MD – No relevant financial relationships to disclose
  • Michael Wechsler, MD, MMSc – AstraZeneca5; Boehringer-Ingelheim5; Boston Scientific5; Genentech5; GlaxoSmithKline5; Novartis5; Sanofi /Regeneron5, Teva5
  • Jinoos Yazdany, MD – NIH/NIAMS2; Agency for Healthcare Research and Quality2; Centers for Disease Control and Prevention2; Astra Zeneca5; Eli Lilly5

Contact Info / Inquiries

American College of Rheumatology
education@rheumatology.org
404-633-3777, ext. 381

© 2020 American College of Rheumatology.  All rights reserved.  Website & Privacy Policies | Sitemap | Help | Contact Us